Last reviewed · How we verify
Anticoagulation treatment.
Anticoagulation treatment. is a Anticoagulant Small molecule drug developed by Samsung Medical Center. It is currently in Phase 2 development for Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, Treatment of deep vein thrombosis and pulmonary embolism.
Anticoagulation via inhibition of vitamin K-dependent clotting factors
Anticoagulation via inhibition of vitamin K-dependent clotting factors Used for Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, Treatment of deep vein thrombosis and pulmonary embolism.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Cardiovascular Phase 3 risk
-2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Anticoagulation treatment. |
|---|---|
| Sponsor | Samsung Medical Center |
| Drug class | Anticoagulant |
| Target | Vitamin K-dependent clotting factors |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
This is achieved through the inhibition of vitamin K-dependent clotting factors, which are essential for the coagulation cascade. The exact mechanism involves the inhibition of factors II, VII, IX, and X.
Approved indications
- Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation
- Treatment of deep vein thrombosis and pulmonary embolism
Common side effects
- Major bleeding
- Gastrointestinal bleeding
- Hemorrhage
Key clinical trials
- Anticoagulation in Emergency General Surgery
- Safety and Efficacy of Low-dose Anticoagulation With Argatroban and Enoxaparin on ECMO (PHASE2)
- Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure (PHASE4)
- Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism (PHASE4)
- OPTIA-AF Trial: Rhythm-Guided Antithrombotic Strategy After AF Ablation (PHASE4)
- Impact of Ligament of Marshall Resection on Atrial Fibrillation Occurrence in Patients Undergoing Coronary Artery Bypass Grafting: A Randomized Controlled Trial (NA)
- Neutrophil and Monocyte Deactivation Via the SeLective CytopheretIc Device - A Randomized Clinical Trial in Acute Kidney Injury (NA)
- WATCHMAN FLX Pro European Registry (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anticoagulation treatment. CI brief — competitive landscape report
- Anticoagulation treatment. updates RSS · CI watch RSS
- Samsung Medical Center portfolio CI
Frequently asked questions about Anticoagulation treatment.
What is Anticoagulation treatment.?
How does Anticoagulation treatment. work?
What is Anticoagulation treatment. used for?
Who makes Anticoagulation treatment.?
What drug class is Anticoagulation treatment. in?
What development phase is Anticoagulation treatment. in?
What are the side effects of Anticoagulation treatment.?
What does Anticoagulation treatment. target?
Related
- Drug class: All Anticoagulant drugs
- Target: All drugs targeting Vitamin K-dependent clotting factors
- Manufacturer: Samsung Medical Center — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation
- Indication: Drugs for Treatment of deep vein thrombosis and pulmonary embolism
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing